是否使用对比剂?评估肝胆对比剂在肝脏FDG-PET/MR中诊断准确性的前瞻性研究
这项前瞻性单中心诊断准确性研究纳入60例经组织学确诊的腹部恶性肿瘤伴恶性肝病变患者,评估单独FDG-PET、非增强PET/MR及增强PET/MR(含或不含肝胆期)的诊断效能。含肝胆期的增强FDG-PET/MR诊断准确性最高(97%),敏感性97.8%,特异性95.2%;加入肝胆期显著提高特异性(75.6%至95.2%,p=0.013)并能检出更小病灶(中位大小7 mm vs 19 mm,p=0.00017)。
要点
- 含肝胆期的增强FDG-PET/MR诊断准确性达97%,敏感性97.8%,特异性95.2%。
- 加入肝胆期使特异性从75.6%提高至95.2%(p=0.013)。
- 含肝胆期可检出更小病灶(中位大小7 mm vs 19 mm,p=0.00017)。
核心结论
- 纳入肝胆对比剂可显著提升FDG-PET/MR对肝脏恶性肿瘤的诊断效能,尤其在检出较小或边界不清病灶方面。
- 作者认为这些发现支持将肝胆期整合入PET/MR工作流程以优化肝病灶检出与分期。
研究设计与样本
- 前瞻性单中心诊断准确性研究,纳入60例经组织学确诊的腹部恶性肿瘤伴恶性肝病变患者。
- 每例患者接受全身FDG-PET/MR,包括上腹部专用成像:非增强、增强不含肝胆期、增强含肝胆期。
- 由三名盲法放射科医师独立阅片并以共识方式评估。
- 参考标准为组织病理学或随访影像。
- 计算敏感性、特异性、阳性预测值、阴性预测值及诊断准确性,采用Fisher精确检验和Mann-Whitney U检验进行统计比较。
主要发现
- 共识别134个恶性肝病变(38个原发肿瘤,96个转移灶)。
- 含肝胆期的增强FDG-PET/MR诊断准确性最高(97%),敏感性97.8%,特异性95.2%。
- 非增强FDG-PET/MR准确性67%,敏感性78%,特异性44%。
- 单独FDG-PET准确性最低(52%)。
- 加入肝胆期显著提高特异性(75.6%至95.2%,p=0.013),并能检出更小病灶(中位大小7 mm vs 19 mm,p=0.00017)。
关键数值与推荐
- 含肝胆期的增强FDG-PET/MR:诊断准确性97%,敏感性97.8%,特异性95.2%。
- 非增强FDG-PET/MR:准确性67%,敏感性78%,特异性44%。
- 单独FDG-PET:准确性52%。
- 加入肝胆期前后特异性分别为75.6%和95.2%(p=0.013)。
- 含肝胆期检出的病灶中位大小7 mm,不含肝胆期为19 mm(p=0.00017)。
临床怎么用
- 作者认为这些发现支持将肝胆期整合入PET/MR工作流程以优化肝病灶检出与分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of hepatobiliary contrast-enhanced imaging in the evaluation of liver malignancies in FDG-PET/MR remains underexplored. The aim of this study was to assess the diagnostic performance of stand-alone FDG-PET, non-contrast-enhanced (NCE) PET/MR, and contrast-enhanced (CE) PET/MR with and without hepatobiliary phase (HBP). METHODS: This prospective, single-center diagnostic accuracy study enrolled 60 patients with histologically confirmed abdominal malignancies and malignant liver lesions. Each patient underwent whole-body FDG-PET/MR, including dedicated upper abdominal imaging with NCE, CE without HBP, and CE with HBP. Three blinded radiologists independently evaluated the images in consensus. The reference standard was histopathology or follow-up imaging. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. Fisher's exact test and Mann-Whitney U test were used for statistical comparisons. RESULTS: A total of 134 malignant liver lesions (38 primary tumors, 96 metastases) were identified. CE FDG-PET/MR with HBP achieved the highest diagnostic accuracy (97%), sensitivity (97.8%), and specificity (95.2%). NCE FDG-PET/MR had an accuracy of 67%, sensitivity of 78%, and specificity of 44%, while stand-alone FDG-PET had the lowest accuracy (52%). The addition of HBP significantly improved specificity (75.6-95.2%, p = 0.013) and enabled detection of smaller lesions (median size 7 mm vs. 19 mm, p = 0.00017). CONCLUSION: The inclusion of hepatobiliary contrast significantly enhances the diagnostic performance of FDG-PET/MR for liver malignancies, particularly in detecting small or poorly defined lesions. These findings support the integration of HBP into PET/MR workflows to optimize liver lesion detection and staging. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Asmundo L, Furtado F, Delaney F, et al. To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40343495. doi:10.1007/s00259-025-07333-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。